Pulmonary hypertension is a progressive disease that is classified into 5 clinical subgroups, leading to the right ventricular failure and high mortality. The 6th World Symposium on Pulmonary Hypertension Task Force defined pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) diagnosis as a mean pulmonary arterial pressure (mPAP) >20 mmHg, a pulmonary arterial wedge pressure (PAWP) ≤15 mmHg and a pulmonary vascular resistance (PVR) ≥3 Wood units assessed by right heart catheterization (RHC) at rest [1].
